Adi Gilboa-Geffen
Chief Technology Officer Eleven Therapeutics
Adi Gilboa-Geffen is a seasoned technology executive currently serving as the Chief Technology Officer at Eleven Therapeutics. With a strong foundation in research and development, Adi’s expertise spans across product innovation, scientific research, and leadership, primarily focusing on the biotechnology and life sciences industries. Adi’s career trajectory is marked by significant leadership roles and contributions to the biotech industry, including roles as Senior VP of Product R&D at Eleven Therapeutics and Advisor at DOTS Technology Corp. Adi’s professional overview includes a unique blend of scientific expertise, product development acumen, and leadership capability, positioning for continued impact and growth in the biotech field.
Seminars
- Utilizing the xRNA™ platform and “combinatorial genetics” to identify and silence high-impact metabolic targets, providing a “once-to-twice-a-year” dosing convenience that eliminates the daily or weekly “jab fatigue” associated with current peptide therapies
- Matching the durability of genetic interventions with a programmable siRNA design to offer a potent maintenance alternative, potentially capturing a dominant share of the post-incretin “transition market” by 2030 as payers demand therapies that prevent the $100B+ biological “rebound effect”
- Optimizing the metabolic “hand-off” protocol by transitioning patients from acute GLP-1 induction to RNA-based physiological regulation, ensuring permanent appetite control and improved insulin sensitivity without the “peaks and troughs” or gastrointestinal side effects of chronic hormonal supplementation
